Family Medicine Doctors in Girard, PA Accepting Medicare
4 Family Medicine doctors found. Showing 1 - 4
 Dr. Joshua Czerwinski, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5165 Imperial Pkwy, Girard, PA 16417 Phone: 814-774-3128 Fax: 814-774-0915 |
Warren J Beaver, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1135 Lake St, Girard, PA 16417 Phone: 814-774-3155 |
 Lisa Ann Treusch, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5165 Imperial Pkwy, Girard, PA 16417 Phone: 814-774-3128 Fax: 814-774-0915 |
Leah M Campbell, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5165 Imperial Pkwy, Girard, PA 16417 Phone: 814-774-3128 Fax: 814-774-0915 |
News Archive
Molecule produced by brain acts as natural defence mechanism against cannabis
Two INSERM research teams led by Pier Vincenzo Piazza and Giovanni Marsicano (INSERM Unit 862 "Neurocentre Magendie" in Bordeaux) recently discovered that pregnenolone, a molecule produced by the brain, acts as a natural defence mechanism against the harmful effects of cannabis in animals.
Sen. Barrasso warns of health insurance marketplace cost 'sticker shock'
The former orthopedic surgeon from Wyoming also warned that the law is too expensive and used the weekly GOP address Saturday to push for its repeal.
Covalon completes non-brokered private placement comprised of 750 units
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
› Verified 6 days ago